Retina

Cleveland Eye Bank Foundation (CEBF) will feature nine researchers from three eye institutions on February 15, from 3 to 5 pm Eastern, for its second annual virtual vision research symposium.

According to the companies, a social media initiative will include donation to Prevent Blindness’ Sight-Saving Fund.

The university recently launched its Center for Neuronal Longevity, which brings together a multidisciplinary team to address unmet needs in vision loss and other neurological diseases.

Spect’s mobile device will enable providers to conduct critical eye screenings anywhere in a matter of minutes.

Firas Rahhal, MD, discusses Outlook Therapeutics’ Phase 3 pivotal NORSE TWO trial for ONS-5010.

Faricimab is the first and only FDA-approved medicine targeting two distinct pathways, Ang-2 and VEGF-A, that often cause retinal diseases that may cause vision loss.

Joshua Mali, MD, shares how the FDA-approved faricimab-svoa (Vabysmo, Genentech) will change the treatment landscape for wet AMD and DME.

A team of investigators at the University of California, Irvine have found that inhibiting ceramide accumulation in retina protects photoreceptors improves vision

A team of investigators at the RIKEN Center for Biosystems Dynamics Research in Japan have used a genetic modification to improve human-derived retina transplants grown in the lab.

Organization makes a commitment to expand translational research acceleration program and fund career development award.

Work by a team of investigators is shedding light on the severity for gene variants and establishing outcome measures for therapeutic trials.

A study finds acceptable outcomes, vision, and microperimetry improvements at higher doses.

This Bascom Palmer Eye Institute 2-day virtual scientific program promises a distinguished international faculty who will share the latest developments in imaging, translational research, and clinical trials as well as the impact these advances will have on clinical ophthalmology.

Nanoscope Therapeutics has received IND clearance from the FDA to begin a Phase 2 trial of its Multi-Characteristic Opsin ambient-light activatable optogenetic monotherapy to restore vision in Stargardt patients.

Across four studies, about half of eligible faricimab patients were able to go 4 months between treatments, and approximately three-quarters could be treated every 3 months or longer. Two papers published in The Lancet highlight one-year results.

A partnership that includes BALANCED Media|Technology, the Retina Foundation of the Southwest and Southern Methodist University is seeking a patent for machine learning software for OCT images aids in identity progression and treatment options

A team of investigators are working on a simple test that may someday identify those who can stop therapy.

The difference between retina’s biological age and person’s real age linked to heightened death risk, with a team of Australian investigators finding that evidence suggests the microvasculature in the retina may be a reliable indicator of the overall health of the body’s circulatory system and the brain.

Since joining the foundation in 2018, Menzo has been involved in the formation of the Retinal Degeneration Fund, the venture arm of Foundation Fighting Blindness.

A University of California Davis study shows that small serving of the fruit increased protective pigments in the eye.

According to the company, biped.ai includes a comfortable and lightweight collar fitted with 3d cameras that continuously monitor a 170° field of view for the user detecting, tracking and predicting the trajectories of all surrounding elements a few seconds in advance.

According to researchers, gaining a good understanding of what Musashi proteins do and how to manipulate their function could lead to the development of a universal therapy for blinding diseases.

ASCENT, REGENXBIO’s Phase III clinical trial conducted in partnership with AbbVie, is expected to enroll patients in the United States and Canada, with pivotal trials expected to support BLA submission for RGX-314 in 2024.

Ted Leng, MD, discusses his IRIS Registry analysis presentation regarding variations in vitreoretinal physician utilization of ancillary testing.

The grant will provide Steven DeVries, MD, PhD, the opportunity to travel to Kyoto, Japan and learn from scientists at Ritsumeikan University about the process of growing 3D retinal organoids from stem cells, a technique first developed in Japan.